Tags

Type your tag names separated by a space and hit enter

Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation.
Climacteric. 2007 Dec; 10(6):471-9.C

Abstract

OBJECTIVES

Equol, a gut bacterial metabolite of the isoflavone daidzein, has been associated with beneficial health effects. Recent studies indicate that women with intestinal capacity to convert daidzein to equol also have the capacity to alter steroid metabolism and bioavailability of estrogens.

METHODS

We evaluated whether individual equol production capability, while not consuming soy supplement, was associated with lower blood pressure in postmenopausal women using tibolone. In addition, in a randomized, placebo-controlled, cross-over trial we assessed the effect of soy supplementation on blood pressure in both equol-producing (n = 20) and non-equol-producing (n = 20) women using tibolone. Blood pressure was recorded with a validated oscillometric technique.

RESULTS

The circulating equol levels rose 20-fold in the equol producers and 1.9-fold in the non-equol producers. At baseline, systolic blood pressure (129.9 +/- 2.6 vs. 138.5 +/- 3.1 mmHg, p = 0.02), diastolic blood pressure (72.2 +/- 1.5 vs. 76.6 +/- 1.3 mmHg, p = 0.01) and mean arterial blood pressure (93.5 +/- 1.7 vs. 99.9 +/- 1.8 mmHg, p = 0.007) were lower in equol producers compared to non-equol producers. Soy supplementation had no effect on blood pressure in either group, whereas the baseline differences persisted.

CONCLUSIONS

Postmenopausal women using tibolone characterized as equol producers had lower blood pressure compared to non-equol producers. Soy supplementation for 2 months had no blood pressure-lowering effect.

Authors+Show Affiliations

Wake Forest University School of Medicine, Comparative Medicine Clinical Research Center, Winston-Salem, NC, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18049940

Citation

Törmälä, R M., et al. "Individual Differences in Equol Production Capability Modulate Blood Pressure in Tibolone-treated Postmenopausal Women: Lack of Effect of Soy Supplementation." Climacteric : the Journal of the International Menopause Society, vol. 10, no. 6, 2007, pp. 471-9.
Törmälä RM, Appt S, Clarkson TB, et al. Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation. Climacteric. 2007;10(6):471-9.
Törmälä, R. M., Appt, S., Clarkson, T. B., Tikkanen, M. J., Ylikorkala, O., & Mikkola, T. S. (2007). Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation. Climacteric : the Journal of the International Menopause Society, 10(6), 471-9.
Törmälä RM, et al. Individual Differences in Equol Production Capability Modulate Blood Pressure in Tibolone-treated Postmenopausal Women: Lack of Effect of Soy Supplementation. Climacteric. 2007;10(6):471-9. PubMed PMID: 18049940.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation. AU - Törmälä,R M, AU - Appt,S, AU - Clarkson,T B, AU - Tikkanen,M J, AU - Ylikorkala,O, AU - Mikkola,T S, PY - 2007/12/1/pubmed PY - 2008/3/15/medline PY - 2007/12/1/entrez SP - 471 EP - 9 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 10 IS - 6 N2 - OBJECTIVES: Equol, a gut bacterial metabolite of the isoflavone daidzein, has been associated with beneficial health effects. Recent studies indicate that women with intestinal capacity to convert daidzein to equol also have the capacity to alter steroid metabolism and bioavailability of estrogens. METHODS: We evaluated whether individual equol production capability, while not consuming soy supplement, was associated with lower blood pressure in postmenopausal women using tibolone. In addition, in a randomized, placebo-controlled, cross-over trial we assessed the effect of soy supplementation on blood pressure in both equol-producing (n = 20) and non-equol-producing (n = 20) women using tibolone. Blood pressure was recorded with a validated oscillometric technique. RESULTS: The circulating equol levels rose 20-fold in the equol producers and 1.9-fold in the non-equol producers. At baseline, systolic blood pressure (129.9 +/- 2.6 vs. 138.5 +/- 3.1 mmHg, p = 0.02), diastolic blood pressure (72.2 +/- 1.5 vs. 76.6 +/- 1.3 mmHg, p = 0.01) and mean arterial blood pressure (93.5 +/- 1.7 vs. 99.9 +/- 1.8 mmHg, p = 0.007) were lower in equol producers compared to non-equol producers. Soy supplementation had no effect on blood pressure in either group, whereas the baseline differences persisted. CONCLUSIONS: Postmenopausal women using tibolone characterized as equol producers had lower blood pressure compared to non-equol producers. Soy supplementation for 2 months had no blood pressure-lowering effect. SN - 1369-7137 UR - https://www.unboundmedicine.com/medline/citation/18049940/Individual_differences_in_equol_production_capability_modulate_blood_pressure_in_tibolone_treated_postmenopausal_women:_lack_of_effect_of_soy_supplementation_ DB - PRIME DP - Unbound Medicine ER -